Drug intelligence / Profile preview

choline c 11

Development stage
Approved
Lead developer
Mayo Clinic
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Choline C 11 is a radiopharmaceutical used as a diagnostic imaging agent in positron emission tomography (PET) scans. It consists of choline labeled with the radioactive isotope carbon-11 (^11C). The drug is primarily indicated for PET imaging in patients with suspected recurrent prostate cancer when other imaging modalities such as bone scintigraphy, CT, or MRI are non-informative. Choline is an essential precursor for the biosynthesis of cell membrane phospholipids; its uptake and incorporation into cell membranes are increased in rapidly proliferating tumor cells due to elevated phospholipid synthesis and choline kinase activity. After intravenous administration, ^11C-choline accumulates preferentially in tissues with high cellular proliferation rates—such as tumors—enabling their detection by PET scanning. The agent has also shown promise for identifying overactive parathyroid glands when other tests fail[1][3][4][5][6][8].

Brand names
Choline C 11
Other names
^[11C]choline^[11C]choline chloride
02

Targets

CHT1 (High-affinity choline transporter 1)CHKA (Choline kinase)

Beyond the preview

Go deeper on choline c 11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on choline c 11.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call